VivoSeq
Other

Cystitis

42

Pipeline Programs↗

12

Active Trials↗

15

Companies Involved↗

Cystitis is a moderately active landscape with 42 programs across 15 companies. The most active players are Sanofi, Novo Nordisk, Paratek Pharmaceuticals Inc. 10 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

80/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Novo Nordisk logo

Novo Nordisk

1 program

Phase 2P

Paratek Pharmaceuticals Inc

1 program

Phase 2L

Lipella Pharmaceuticals, Inc.

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical10

Alcohol

Astellas

Amikacin

Insmed Incorporated

Cefpodoxime

Washington University School of Medicine

Bearberry

University of Pecs

Monural

PharmaLinea Ltd.

Phase 16

Probenecid

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Exosomes

Guangzhou Bio-gene Technology Co., Ltd

Sodium Hyaluronate

Sanofi

Medication

NYU Langone Health

Gelatin Sponge Sheet

Tianjin Medical University Eye Hospital

Phase 27

Gentamicin

Schering-Plough

Cidofovir

Gilead

Decidual Stromal Cells

Karolinska Institutet

Omadacycline

Paratek Pharmaceuticals Inc

Nitrofurantoin X 5 Days

University of Washington

Phase 39

Ciprofloxacin

Bayer

Hyperbaric Oxygen

Intermountain Health Care, Inc.

Pentosan Polysulfate Sodium

Wim Janssens

Norfloxacin

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Raphamin

Materia Medica Holding

Approved10

Nitrofurantoin

Procter and Gamble

Ceftazidime

Philadelphia Eye Associates

Ibuprofen

Kenvue Brands

Amoxicillin

Global Antibiotics Research and Development Partnership

Oxybutynin

Wim Janssens

Analysis

Modality Breakdown

98%

Small molecule

48 of 49 classified programs — the dominant modality here.

2%ALL OTHERSCell therapy12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 98% of 52 pipeline programs.

Analysis

Trial Status

41

clinical trials

Completed20 · 49%
Not yet recruiting5 · 12%
Unknown status4 · 10%
Recruiting4 · 10%
Withdrawn3 · 7%
Active, not recruiting2 · 5%
Other3 · 7%

Clinical Trials

Trial Activity

41 trials

Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Recruiting·—·N/A·NCT05227937·75 enrolled
Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis
Recruiting·MMahidol University·Phase 4·NCT07186465·100 enrolled
Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial
Recruiting·NNational Taiwan University Hospital·Phase 2/3·NCT05245591·72 enrolled
Chronic Radiation Cystitis and Effect of Hyperbaric Oxygen Therapy on Patient Reported Outcomes and Urine Inflammatory Biomarkers
Recruiting·—·N/A·NCT07368647·100 enrolled
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01295645·27 enrolled
Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis
Active, not recruiting·MMateria Medica Holding·Phase 3·NCT06284265·415 enrolled
COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
Not yet recruiting·—·Phase 4·NCT06518291·392 enrolled
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
Not yet recruiting·Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 3·NCT06815549·280 enrolled
Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis
Not yet recruiting·PPHARMENTERPRISES LLC·Phase 2·NCT06391164·280 enrolled
Clinical Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Combined With Sodium Hyaluronate Intravesical Instillation in the Treatment of Radiation Cystitis
Not yet recruiting·FFujian Medical University Union Hospital·Phase 1·NCT07665619·48 enrolled
Study to Evaluate the Efficacy and Safety of Colipral® (Probiotic Strain Escherichia Coli 5C (ECP24®)) in the Prevention of Recurrent Cystitis in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Not yet recruiting·LLiaquat University of Medical & Health Sciences·Preclinical·NCT07676604·134 enrolled
Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis
Enrolling by invitation·—·Phase 1·NCT07016451·40 enrolled
Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract
Completed·SSamsung Medical Center·Phase 4·NCT02366676·105 enrolled
Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis
Completed·FFundação Educacional Serra dos Órgãos·Phase 4·NCT03379389·284 enrolled
A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department
Completed·UUniversity of Iowa·Phase 4·NCT01749605·35 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)